Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy

Clinical Rheumatology

Volumn 25, Issue 4, 2006, Pages 515-519

  Chiu, Shih Jung ^a   Ou, Liang Shiou ^a   Tsai, Tien Lung ^b   Hung, Iou Jih ^a   Huang, Jing Long ^a,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL PINGTUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

Author keywords

Cyclophosphamide; Hyperlipidemia; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ALBUMIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; MESNA; PREDNISOLONE; TRIACYLGLYCEROL;

ADOLESCENT; ALBUMIN BLOOD LEVEL; ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAIR LOSS; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; INFECTION COMPLICATION; KIDNEY BIOPSY; LABORATORY DIAGNOSIS; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MALE; NAUSEA AND VOMITING; NEUTROPHIL COUNT; PATIENT MONITORING; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; SEROLOGY; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ADOLESCENT; BLOOD CELL COUNT; CHILD; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; MALE; PREDNISOLONE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746551066     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-005-0081-5     Document Type: Article

References (21)

1. Austin HA III, Klippel JH, Balow JE, leRiche NG, Steinberg AD, Plotz PH et al (1986) Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619
2. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34(8):945-949
3. Boumpas DT, Austin HA III, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745
4. Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 125:549-557
5. Zonana-nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801-1808
6. Rees L, Chantler C (1990) Growth and endocrine function in children receiving long-term steroid therapy for renal disease. Acta Paediatr Scand Suppl 366:93-96
7. Silverman ED, Lang B (1997) An overview of the treatment of childhood SLE. Scand J Rheumatol 26:241-246
8. Lehman TJA (2001) Modern treatment of childhood SLE. Clin Exp Rheumatol 19:487-489
9. Lehman TJA, Sherry DD, Wanger-Weiner L, McCurdy DK, Emery HM, Magilavy DB, Kovalesky A (1989) Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 114:1055-1060
10. Lehman TJA, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 136:243-247
11. Barbano G, Gusmano R, Damasio B, Alpigiani MG, Buoncompagni A, Gattorno M, Perfumo F (2002) Childhood-onset lupus nephritis: A single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 15:123-129
12. Al Salloum AA (2003) Cyclophosphamide therapy for lupus nephritis: Poor renal survival in Arab children. Pediatr Nephrol 18:357-361
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
14. Balow JE (1990) Treatment and monitoring of patient with lupus nephritis. Nephrol Dial Transplant 5(suppl 1):S58-S59
15. Mc Curdy DK, Lehman TJA, Bernstein B, Hanson V, King KK, Nadorra R, Landing BH (1992) Lupus nephritis: Prognostic factors in children. Pediatrics 89:240-246
16. Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoprotenemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859-863
17. Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in systemic lupus erythematosus. J Rheumatol 21:1264-1267
18. Bora EF, Bonfa E (1997) Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533-539
19. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359-363
20. Wallace DJ, Metzger AL, Stretcher V, Turnbull BA, Kern PA (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of corticosteroids on lipids. Am J Med 89:322-326
21. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA (1997) Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 6:254-257